Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 37
Filtrar
1.
Hypertension ; 81(7): 1637-1643, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38752357

RESUMEN

BACKGROUND: Prediabetes has garnered increasing attention due to its association with cardiovascular conditions, especially hypertension, which heightens the risk of prefrailty and frailty among older individuals. METHODS: We screened elders with prefrail hypertension from March 2021 to January 2023. We assessed the correlation linking cognitive dysfunction (Montreal Cognitive Assessment score), insulin resistance (triglyceride-to-glucose index), and physical impairment (5-meter gait speed). Then, we measured the risk of developing frailty after a 1-year follow-up period, adjusting the outcome using multivariable Cox regression analysis. We also investigated the impact of administering 500 mg of metformin once daily to a subset of frail subjects for an additional 6 months. RESULTS: We assessed the relationship between the triglyceride-to-glucose index and the Montreal Cognitive Assessment score, observing a significant correlation (r, 0.880; P<0.0001). Similarly, we analyzed the association between the triglyceride-to-glucose index and 5-meter gait speed, uncovering a significant link between insulin resistance and physical impairment (r, 0.809; P<0.0001). Prediabetes was found to significantly (P<0.0001) elevate the risk of frailty development compared with individuals without prediabetes by the end of the 1-year follow-up, a finding confirmed via multivariable analysis with Cox regression. Furthermore, among the subgroup of subjects who developed frailty, those who received metformin exhibited a significant decrease in frailty levels (P<0.0001). CONCLUSIONS: Insulin resistance and prediabetes play substantial roles in the development of cognitive and physical impairments, highlighting their importance in managing hypertension, even before the onset of frank diabetes. Metformin, a well-established drug for the treatment of diabetes, has shown favorable effects in mitigating frailty.


Asunto(s)
Fragilidad , Hipertensión , Hipoglucemiantes , Metformina , Estado Prediabético , Humanos , Metformina/uso terapéutico , Masculino , Estado Prediabético/tratamiento farmacológico , Anciano , Femenino , Fragilidad/epidemiología , Hipertensión/tratamiento farmacológico , Hipertensión/epidemiología , Hipoglucemiantes/uso terapéutico , Resistencia a la Insulina , Anciano Frágil , Anciano de 80 o más Años , Disfunción Cognitiva/epidemiología , Disfunción Cognitiva/prevención & control , Disfunción Cognitiva/etiología , Glucemia/efectos de los fármacos , Glucemia/metabolismo
2.
J Clin Endocrinol Metab ; 109(2): e495-e507, 2024 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-37820735

RESUMEN

CONTEXT: In 2005, a nationwide program of iodine prophylaxis on a voluntary basis was implemented in Italy by law. However, recent data on iodine status are lacking. OBJECTIVE: The aim of this study was to evaluate efficiency, effectiveness, and possible adverse effects (increased occurrence of thyroid autoimmunity and hyperthyroidism) of the Italian iodine prophylaxis program. METHODS: From 2015 to 2019, a nationwide survey was performed. The use of iodized salt was evaluated in a sample of 164 593 adults and in 998 school canteens. A sample of 4233 schoolchildren (aged 11-13 years) was recruited to assess urinary iodine concentration, prevalence of goiter, and thyroid hypoechogenicity on ultrasound, with the latter being an indirect indicator of thyroid autoimmunity. Neonatal TSH values of 197 677 infants screened in regions representative of Northern, Central, and Southern Italy were analyzed to investigate the percentage of TSH values >5.0 mIU/L. Data on methimazole prescriptions were analyzed as indirect indicators of new cases of hyperthyroidism. RESULTS: The prevalence of the use of iodized salt was 71.5% in adult population and 78% in school canteens. A median urinary iodine concentration of 124 µg/L, a prevalence of goiter of 2.2%, and a prevalence of thyroid hypoechogenicity of 5.7% were observed in schoolchildren. The percentage of neonatal TSH values >5.0 mIU/L resulted still higher (5.1%) than the World Health Organization threshold of 3.0%, whereas the prescriptions of methimazole showed a reduction of 13.5%. CONCLUSION: Fifteen years of iodine prophylaxis have led to iodine sufficiency in Italy, although there still is concern about iodine nutritional status during pregnancy.


Asunto(s)
Bocio , Hipertiroidismo , Yodo , Adulto , Femenino , Lactante , Embarazo , Recién Nacido , Humanos , Niño , Metimazol , Bocio/epidemiología , Bocio/prevención & control , Cloruro de Sodio Dietético , Italia/epidemiología , Prevalencia , Tirotropina
3.
Sci Rep ; 12(1): 21827, 2022 12 17.
Artículo en Inglés | MEDLINE | ID: mdl-36528736

RESUMEN

Microplastics of fibrous shape are esteemed to be the most abundant micro-debris form present in the environment. Despite the occurrence of microfibers in fish may pose a risk to human health, the literature is scarce regarding studies on the contamination in commercial marine fish mostly due to methodological issues. In this study, a versatile approach, able to discriminate among natural and synthetic microfibers according to the evaluation of specific morphological features, is proposed in farmed mussels (Mytilus galloprovincialis). The approach was useful to determine that microfibers were present in 74% of mussel samples, with a mean number of 14.57 microfibers/individual, corresponding to 3.13 microfibers/g w.w. A negative correlation between the size of analysed mussels and the amount of microfibers/g w.w. was detected, showing that smaller specimens contained more microfibers than the larger ones. This work paves the way to further studies aimed to adequately assess the risk that microfibers may pose to marine biota, also considering the commercial value as seafood items of many species of the Mytilus genus and the potential implication for human exposure.


Asunto(s)
Mytilus , Contaminantes Químicos del Agua , Animales , Humanos , Plásticos/análisis , Monitoreo del Ambiente , Contaminantes Químicos del Agua/análisis , Alimentos Marinos/análisis
4.
Nutrients ; 14(6)2022 Mar 11.
Artículo en Inglés | MEDLINE | ID: mdl-35334835

RESUMEN

Lactobacilli constitute the dominant microbiota in many fermented foods and comprise widely used probiotics. However, these bacteria cause rare infections mostly in diabetic and immunocompromised subjects in presence of risk factors such as prosthetic hearth valves and dental procedures or caries. The scope of this survey was re-assessing the pathogenic potential of lactobacilli based on the infection case reports published in the last three years. In 2019, 2020, and 2021, total of 17, 15, and 16 cases, respectively, including endocarditis, bacteremia, and other infections, were reported. These annual numbers are higher than those observed previously. Lacticaseibacillus rhamnosus (13 cases), comprising strain GG (ATCC 53103) with established applications in healthcare, L. paracasei (7 cases), Lactobacillus acidophilus (5 cases), L. jensenii (5 cases), Lactiplantibacillus plantarum (3 cases), L. paraplantarum, L. delbrueckii subsp. delbrueckii, L. gasseri, L. paragasseri, Limosilactobacillus fermentum, and L. reuteri (1 case each) were involved. Virulence characterization of two strains that caused infections, a derivative of L. rhamnosus GG and L. paracasei LP10266, indicated that increased biofilm-forming capacity favors pathogenicity and it is determined by variable genetic traits. This survey highlights that the strains of lactobacilli that cause infections are little characterized genetically. Instead, to avoid that these bacteria become a hazard, genetic stability should be periodically re-evaluated by whole genome sequencing (WGS) to ensure that only non-pathogenic variants are administered to vulnerable individuals.


Asunto(s)
Lacticaseibacillus rhamnosus , Microbiota , Probióticos , Humanos , Lactobacillus/genética , Lacticaseibacillus rhamnosus/genética
5.
Ital J Food Saf ; 10(1): 9264, 2021 Mar 11.
Artículo en Inglés | MEDLINE | ID: mdl-33747985

RESUMEN

Microplastics (MPs) are an emerging threat to marine ecosystems. One of the primary environmental risks is their bioavailability for aquatic organisms. Some fish and bivalves are of particular interest because their feeding strategies expose them to particles present in the water column. The aim of the study was to assess an extraction method in order to isolate and quantify MPs from fish gastrointestinal tract (n.8) and muscle (n.4), and bivalves (n.8) samples. The accuracy of the method was assessed through the calculation of the recovery percentage in samples spiked with a known number of MPs using microscopic observation. Successively, the extraction was preliminarily applied on n.20 mussels collected from mariculture plants of the Tyrrhenian and the Adriatic Sea. The results of the digestion protocol showed an average extraction yield of 80% in fish gastrointestinal tracts, 90% in fish muscle samples, and 95% in mussels. Preliminary analysis carried out on farmed mussels showed an average abundance of 3.8 items/individual, and 0.5 items/g of tissue, among those black, was the most represented color.

6.
Acta Haematol ; 143(2): 155-162, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31533096

RESUMEN

Refractory anaemia (RA) among myelodysplastic syndrome (MDS) is associated with a partial functional iron deficit and may require transfusions. In low-risk lymphoma and solid tumour patients, iron support improves erythropoietin (EPO) cost-effectiveness in treating anaemia. The aim of this study is to see if oral sucrosomial iron support improves the cost-effectiveness of EPO treatment in MDS patients affected by low-risk RA. We treated patients with EPO only or with EPO plus oral sucrosomial iron or intravenous (i.v.) iron. The need for transfusions was lowest in the group taking oral iron (p = 0.016) or not receiving supplementation at all (p = 0.022). We compared costs of EPO with i.v. ferric gluconate or oral sucrosomial iron supplementation or no iron supplementation. The oral iron group had fewer side effects, fewer patient medical visits in the out-patient setting, and fewer transfusions; this led to higher savings on direct hospital costs and indirect patient costs (lost days at work) and translated into a 50% abatement of overall expenditures. EPO treatment-related expenditures in MDS-RA patients were lowest with oral sucrosomial iron supplementation (Sideral®), with a longer interval between EPO administration in maintenance treatment, quicker hemoglobin recovery, lower ferritin increase and fewer blood transfusions.


Asunto(s)
Anemia Refractaria/tratamiento farmacológico , Eritropoyetina/uso terapéutico , Hierro/administración & dosificación , Síndromes Mielodisplásicos/patología , Anciano , Anciano de 80 o más Años , Anemia Refractaria/complicaciones , Anemia Refractaria/economía , Suplementos Dietéticos , Progresión de la Enfermedad , Eritropoyetina/economía , Femenino , Compuestos Férricos/administración & dosificación , Ferritinas/sangre , Costos de la Atención en Salud , Humanos , Italia , Masculino , Síndromes Mielodisplásicos/complicaciones , Resultado del Tratamiento
7.
BMJ Case Rep ; 20142014 Oct 29.
Artículo en Inglés | MEDLINE | ID: mdl-25355748

RESUMEN

Complementary medications and herbal medicine for weight loss have become very popular. We report a case of thyroid dysfunction following the ingestion of a kelp-containing marketed diet in a 45-year-old woman with no previous thyroid disease. Signs of hyperthyroidism occurred shortly after a kelp-containing diet. Hyperthyroidism lasted 2 months and was followed by an overt hypothyroidism. The thyroid scintiscan exhibited an extremely low uptake and colour-Doppler ultrasonography revealed multiple small areas of pulsatile flow. After 3 months of levothyroxine substitutive therapy, normal thyroid function was recovered after levothyroxine discontinuation. This clinical history is compatible with a case of iodine-induced thyrotoxicosis followed by prolonged block of the sodium-iodide symporter activity as a consequence of excessive iodine consumption from kelp. Consumers of marketed diets containing kelp or other iodine-rich ingredients should be advised of the risk to develop a thyroid dysfunction also in the absence of underlying thyroid disease.


Asunto(s)
Dieta Reductora/efectos adversos , Hipertiroidismo/inducido químicamente , Hipotiroidismo/inducido químicamente , Yodo/efectos adversos , Kelp , Femenino , Humanos , Hipotiroidismo/tratamiento farmacológico , Persona de Mediana Edad , Glándula Tiroides/diagnóstico por imagen , Tirotoxicosis/inducido químicamente , Tiroxina/uso terapéutico , Ultrasonografía
8.
Gene ; 534(2): 282-5, 2014 Jan 25.
Artículo en Inglés | MEDLINE | ID: mdl-24211324

RESUMEN

Heterozygous de novo mutations in SOX2 have been reported in approximately 10-20% of patients with unilateral or bilateral anophthalmia or microphthalmia. An additional phenotype of hypopituitarism, with anterior pituitary hypoplasia and hypogonadotropic hypogonadism, has been reported in patients carrying SOX2 alterations. We report a novel heterozygous mutation in the SOX2 gene in a male affected with congenital bilateral anophthalmia, hypogonadotrophic hypogonadism and growth hormone deficiency. The mutation we describe is a cytosine deletion in position 905 (c905delC) which causes frameshift and an aberrant C-terminal domain. Our report highlights the fact that subjects affected with eye anomalies and harboring SOX2 mutations are at high risk for gonadotropin deficiency, which has important implications for their clinical management.


Asunto(s)
Anoftalmos/genética , Anomalías Congénitas/genética , Hormona de Crecimiento Humana/deficiencia , Hormona de Crecimiento Humana/genética , Hipogonadismo/genética , Factores de Transcripción SOXB1/genética , Eliminación de Secuencia , Adolescente , Heterocigoto , Humanos , Hipogonadismo/etiología , Masculino
9.
Neuroendocrinology ; 98(4): 299-310, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24355865

RESUMEN

INTRODUCTION: Hyperprolactinemia has been implicated in the pathogenesis of obesity and glucose intolerance and is reportedly associated with an impaired metabolic profile. The current study aimed at investigating the effects of 12- and 60-month treatment with cabergoline (CAB) on metabolic syndrome (MetS) in patients with prolactinomas. PATIENTS AND METHODS: 61 patients with prolactinomas (13 men, 48 women, 41 with microadenoma, 20 with macroadenoma), aged 34.4 ± 10.3 years, entered the study. In all patients, prolactin (PRL) and metabolic parameters were assessed at diagnosis and after 12 and 60 months of continuous CAB treatment. MetS was diagnosed according to NCEP-ATP III criteria. RESULTS: Compared to baseline, CAB induced a significant decrease in PRL with complete normalization in 93% of patients after the 60-month treatment. At baseline, MetS prevalence was significantly higher in patients with PRL above (34.5%) than in those with PRL lower (12.5%) than the median (129 µg/l, p = 0.03). MetS prevalence significantly decreased after 12 (11.5%, p = 0.039) and 60 (5.0%, p = 0.001) months compared to baseline (28.0%). At both evaluations the lipid profile significantly improved compared to baseline. Fasting insulin and homeostatic model assessment of insulin resistance significantly decreased after 1 year of CAB (p = 0.012 and p = 0.002, respectively) and further improved after 60 months (p = 0.000). The visceral adiposity index significantly decreased after the 60-month treatment (p = 0.000) compared to baseline. At the 5-year evaluation CAB dose was the best predictor of percent decrease in fasting insulin (t = 2.35, p = 0.022). CONCLUSIONS: CAB significantly reduces MetS prevalence and improves the adipose tissue dysfunction index. The improvement in PRL, insulin sensitivity and other metabolic parameters might reflect the direct effect of CAB.


Asunto(s)
Antineoplásicos/uso terapéutico , Ergolinas/uso terapéutico , Enfermedades Metabólicas/tratamiento farmacológico , Neoplasias Hipofisarias/tratamiento farmacológico , Prolactinoma/tratamiento farmacológico , Adiposidad/efectos de los fármacos , Adulto , Antineoplásicos/administración & dosificación , Cabergolina , Relación Dosis-Respuesta a Droga , Ergolinas/administración & dosificación , Ayuno/metabolismo , Femenino , Humanos , Hiperprolactinemia/tratamiento farmacológico , Hiperprolactinemia/epidemiología , Hiperprolactinemia/metabolismo , Insulina/metabolismo , Resistencia a la Insulina , Masculino , Enfermedades Metabólicas/epidemiología , Enfermedades Metabólicas/metabolismo , Síndrome Metabólico , Neoplasias Hipofisarias/epidemiología , Neoplasias Hipofisarias/metabolismo , Prevalencia , Pronóstico , Prolactina/sangre , Prolactinoma/epidemiología , Prolactinoma/metabolismo , Estudios Prospectivos , Factores de Tiempo , Resultado del Tratamiento
10.
Eur J Endocrinol ; 169(3): 359-66, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23824978

RESUMEN

OBJECTIVE: Cabergoline (CAB) has been found to be associated with increased risk of cardiac valve regurgitation in Parkinson's disease, whereas several retrospective analyses failed to detect a similar relation in hyperprolactinemic patients. The current study aimed at investigating cardiac valve disease before and after 24 and 60 months of continuous treatment with CAB only in patients with hyperprolactinemia. SUBJECTS AND METHODS: Forty patients (11 men and 29 women, aged 38.7 ± 12.5 years) newly diagnosed with hyperprolactinemia entered the study. Cumulative CAB dose ranged from 12 to 588 mg (median 48 mg) at 24 months and 48-1260 mg (median 149 mg) at 60 months. All patients underwent a complete trans-thoracic echocardiographic examination. Valve regurgitation was assessed according to the American Society of Echocardiography. RESULTS: At baseline, the prevalence of trace mitral, aortic, pulmonic, and tricuspid regurgitations was 20, 2.5, 10, and 40% respectively, with no patient showing clinically relevant valvulopathy. After 24 months, no change in the prevalence of trace mitral (P=0.78) and pulmonic (P=0.89) regurgitations and of mild aortic (P=0.89) and tricuspid (P=0.89) regurgitations was found when compared with baseline. After 60 months, the prevalence of trace tricuspid regurgitation was only slightly increased when compared with that after 24 months (37.5%; P=0.82), but none of the patients developed significant valvulopathy. No correlation was found between cumulative dose and prevalence or grade of valve regurgitation at both evaluations. Prolactin levels normalized in all patients but one. CONCLUSION: CAB does not increase the risk of significant cardiac valve regurgitation in prolactinomas after the first 5 years of treatment.


Asunto(s)
Antineoplásicos/efectos adversos , Agonistas de Dopamina/efectos adversos , Ergolinas/efectos adversos , Enfermedades de las Válvulas Cardíacas/inducido químicamente , Válvulas Cardíacas/efectos de los fármacos , Neoplasias Hipofisarias/tratamiento farmacológico , Prolactinoma/tratamiento farmacológico , Adulto , Antineoplásicos/administración & dosificación , Antineoplásicos/uso terapéutico , Cabergolina , Estudios de Cohortes , Agonistas de Dopamina/administración & dosificación , Agonistas de Dopamina/uso terapéutico , Monitoreo de Drogas , Diagnóstico Precoz , Ergolinas/administración & dosificación , Ergolinas/uso terapéutico , Femenino , Estudios de Seguimiento , Enfermedades de las Válvulas Cardíacas/diagnóstico por imagen , Enfermedades de las Válvulas Cardíacas/epidemiología , Enfermedades de las Válvulas Cardíacas/fisiopatología , Válvulas Cardíacas/diagnóstico por imagen , Humanos , Italia/epidemiología , Masculino , Persona de Mediana Edad , Prevalencia , Índice de Severidad de la Enfermedad , Factores de Tiempo , Ultrasonografía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...